BBS2

Across TCGA pan-cancer cohorts, BBS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BBS2 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BBS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BBS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where BBS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.827	1.000	.003	27	view →
PDAC	DFS	Tertile	All	0.940	0.654	.002	18	view →
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.021	12	view →
HNSC	DFS	Median	IV	0.595	0.826	.008	10	view →
CCRCC	DFS	Median	III,IV	0.960	0.766	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BBS2–LSCC (DFS)

Open the LSCC breakdown →